Zika virus (ZIKV) has recently emerged as a pandemic associated with severe neuropathology
in newborns and adults 1 . There are no ZIKV-specific treatments or preventatives. …

Betacoronaviruses caused the outbreaks of severe acute respiratory syndrome (SARS) and
Middle East respiratory syndrome, as well as the current pandemic of SARS coronavirus 2 (…

SARS-CoV-2-neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding
SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we isolated …

T follicular helper (Tfh) cells are required to develop germinal center (GC) responses and
drive immunoglobulin class switch, affinity maturation, and long-term B cell memory. In this …

HIV-1 subtype C is the most common HIV-1 group M subtype in Africa and many parts of
Asia. However, to date HIV-1 vaccine candidate immunogens have not induced potent and …

Genetic variation of human immunodeficiency virus (HIV-1) represents a major obstacle for
AIDS vaccine development. To decrease the genetic distances between candidate …

The RV144 Thai trial HIV-1 vaccine of recombinant poxvirus (ALVAC) and recombinant HIV-1
gp120 subtype B/subtype E (B/E) proteins demonstrated 31% vaccine efficacy. Here we …

The HIV-1 envelope (Env) is a key determinant in mediating viral entry and fusion to host
cells and is a major target for HIV vaccine development. While Env is typically about 50% …

Two human monoclonal antibodies (MAbs) (2F5 and 4E10) against the human immunodeficiency
virus type 1 (HIV-1) envelope g41 cluster II membrane proximal external region (MPER…

The development of a vaccine that can induce high titers of functional antibodies against HIV-1
remains a high priority. We have developed an adjuvant based on an oil-in-water …